At $238.49, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) screens as fully valued, with conditions potentially improving on any macro-driven pullback to $228. JNJ just stacked a $1 billion cash acquisition of Firefly Bio on top of a raised 2026 outlook, right as a more dovish Fed leadership backdrop pushes capital toward defensive cash flows.
JNJ is the world’s largest diversified healthcare company, split between Innovative Medicine and MedTech, with a $570.5 billion market cap and AAA credit. The stock has climbed 56.25% over the past year and 16.52% year to date, lifted by oncology momentum, a Dividend King payout, and rotation out of high-multiple tech.
Why the Firefly Bio Deal Reframes the Oncology Story
The bull case starts with the pipeline. DARZALEX hit $3.964 billion in Q1 2026, up 22.5%, CARVYKTI grew 62.1% to $597 million, and RYBREVANT/LAZCLUZE jumped 82.7%. The Firefly Bio buyout adds the Firelink degrader-antibody platform targeting KRAS-driven tumors, paired with a $1 billion-plus cell therapy manufacturing build-out in Pennsylvania.
Management raised guidance to $100.3B–$101.3B in revenue and $11.45–$11.65 in adjusted EPS, and CEO Joaquin Duato said “Curing certain cancers and transforming others into chronic diseases is a realistic goal for the next decade.” A forward P/E near 20x with a beta of 0.256 looks defensible against the broader large-cap pharma group.
Why the Bears See a Stretched Setup
The bear case sits in the income statement and the courtroom. Q1 net income fell 52.4% and free cash flow dropped 55.42% to $1.5 billion, weighed by $330 million in litigation charges. STELARA collapsed 59.7% to $656 million, dragging the Innovative Medicine segment by roughly 920 basis points. A $32 million Los Angeles talc verdict is a reminder that legal tail risk persists.
Shares now sit just under the $250.24 52-week high after a 6.83% weekly run. Insider activity skews neutral, with EVP John Reed selling 11,002 shares at $229.85 in May.
Why Patience May Be Rewarded Near $238
The entry-math case is straightforward. The stock has run from $220.15 a month ago on Firefly Bio enthusiasm, ASCO oncology data, and a steady 3.75% Fed funds rate that supports long-duration pharma cash flows. With an internal price prediction near $237.79, near-term reward looks compressed. A pullback toward $228 would restore more attractive risk/reward without requiring investors to chase strength.
What the Stock and the Analysts Are Telling You
JNJ trades at $238.49 against an analyst consensus target of $252.87, implying roughly 6% upside, with coverage spanning 15 Buy, 8 Hold, and 1 Sell rating. Valuation runs at a trailing P/E of 27 and forward P/E of 20, with a 2.24% dividend yield backed by 64 straight years of hikes.
Performance tells the rotation story. JNJ is up 16.52% year to date while the S&P 500, proxied by SPY, gained roughly 7.7% over the 30 days after JNJ’s April earnings, a clear sign defensive healthcare is back in favor.
The Takeaway: Watching the $228 Level
At $238, Johnson & Johnson screens as fully valued on a risk/reward basis.
The fundamental story is intact. Oncology is compounding, guidance is rising, and the Firefly Bio deal supports the path to double-digit growth by the end of the decade. Yet the stock has absorbed most of that good news in a vertical move from $152.64 a year ago to today.
The signal to reassess is mechanical. A consolidation toward $228, driven by broad-market profit-taking rather than a JNJ-specific crack, would offer a Dividend King with accelerating oncology torque at a forward multiple in the high teens. A reaccelerating STELARA decline, a major adverse talc ruling, or messy execution on the DePuy Synthes separation would shift the risk profile materially to the downside.
The cost of patience is one dividend cycle and roughly 6% of theoretical upside to consensus. The cost of chasing is paying near a 52-week high for a defensive name whose own model sees no near-term upside. Watching the $228 level keeps investors on the right side of that math.
Top Gaining Stocks
Top Losing Stocks